Wenn Sie das Fenster schließen, wird Ihre Konfiguration nicht gespeichert, es sei denn, Sie haben Ihren Artikel in die Bestellung aufgenommen oder zu Ihren Favoriten hinzugefügt.
Klicken Sie auf OK, um das MILLIPLEX® MAP-Tool zu schließen oder auf Abbrechen, um zu Ihrer Auswahl zurückzukehren.
Wählen Sie konfigurierbare Panels & Premixed-Kits - ODER - Kits für die zelluläre Signaltransduktion & MAPmates™
Konfigurieren Sie Ihre MILLIPLEX® MAP-Kits und lassen sich den Preis anzeigen.
Konfigurierbare Panels & Premixed-Kits
Unser breites Angebot enthält Multiplex-Panels, für die Sie die Analyten auswählen können, die am besten für Ihre Anwendung geeignet sind. Unter einem separaten Register können Sie das Premixed-Cytokin-Format oder ein Singleplex-Kit wählen.
Kits für die zelluläre Signaltransduktion & MAPmates™
Wählen Sie gebrauchsfertige Kits zur Erforschung gesamter Signalwege oder Prozesse. Oder konfigurieren Sie Ihre eigenen Kits mit Singleplex MAPmates™.
Die folgenden MAPmates™ sollten nicht zusammen analysiert werden: -MAPmates™, die einen unterschiedlichen Assaypuffer erfordern. -Phosphospezifische und MAPmate™ Gesamtkombinationen wie Gesamt-GSK3β und Gesamt-GSK3β (Ser 9). -PanTyr und locusspezifische MAPmates™, z.B. Phospho-EGF-Rezeptor und Phospho-STAT1 (Tyr701). -Mehr als 1 Phospho-MAPmate™ für ein einziges Target (Akt, STAT3). -GAPDH und β-Tubulin können nicht mit Kits oder MAPmates™, die panTyr enthalten, analysiert werden.
.
Bestellnummer
Bestellinformationen
St./Pkg.
Liste
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Wählen Sie bitte Spezies, Panelart, Kit oder Probenart
Um Ihr MILLIPLEX® MAP-Kit zu konfigurieren, wählen Sie zunächst eine Spezies, eine Panelart und/oder ein Kit.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Spezies
Panelart
Gewähltes Kit
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
96-Well Plate
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
Weitere Reagenzien hinzufügen (MAPmates erfordern die Verwendung eines Puffer- und Detektionskits)
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Platzsparende Option Kunden, die mehrere Kits kaufen, können ihre Multiplex-Assaykomponenten in Kunststoffbeuteln anstelle von Packungen erhalten, um eine kompaktere Lagerung zu ermöglichen.
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Das Produkt wurde in Ihre Bestellung aufgenommen
Sie können nun ein weiteres Kit konfigurieren, ein Premixed-Kit wählen, zur Kasse gehen oder das Bestell-Tool schließen.
AP186P
Sigma-AldrichMouse Anti-Goat IgG Antibody, HRP conjugate, Species Adsorbed
This Mouse anti-Goat IgG Antibody, HRP conjugate, Species Adsorbed is validated for use in ELISA, WB for the detection of Goat IgG.
More>>This Mouse anti-Goat IgG Antibody, HRP conjugate, Species Adsorbed is validated for use in ELISA, WB for the detection of Goat IgG. Less<<
SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.
This Mouse anti-Goat IgG Antibody, HRP conjugate, Species Adsorbed is validated for use in ELISA, WB for the detection of Goat IgG.
Key Applications
ELISA
Western Blotting
Biological Information
Host
Mouse
Species Reactivity
Goat
Antibody Type
Polyclonal Antibody
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Packaging Information
Material Size
1 mL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Bestellnummer
GTIN
AP186P
04053252510670
Documentation
Mouse Anti-Goat IgG Antibody, HRP conjugate, Species Adsorbed SDB
Peculiar composition of epithelial cells in follicle-associated intestinal crypts of Peyer's patches in the rat small intestine. Mantani, Y; Yuasa, H; Nishida, M; Takahara, E; Omotehara, T; Udayanga, KG; Kawano, J; Yokoyama, T; Hoshi, N; Kitagawa, H The Journal of veterinary medical science / the Japanese Society of Veterinary Science
76
833-8
2014
The epithelial cell composition was investigated in the follicle-associated intestinal crypt (FAIC) of rat Peyer's patches. The epithelium of the FAIC mainly consisted of columnar epithelial cells, goblet cells and Paneth cells. The characteristics of secretory granules in Paneth cells and goblet cells of both the FAIC and ordinary intestinal crypts (IC) were almost the same in periodic acid-Schiff (PAS) reaction, Alcian blue (AB) staining and the immunohistochemical detection of lysozymes and soluble phospholipase A2. Both goblet cells and Paneth cells were markedly less frequent on the follicular sides than on the anti-follicular sides of the FAIC. Goblet cells were also markedly less frequent in the follicle-associated epithelium (FAE) than in the ordinary intestinal villi (IV). Indigenous bacteria were more frequently adhered to FAE than to follicle-associated intestinal villi or IV. These findings suggest that the host defense against indigenous bacteria is inhibited on the follicular sides of FAIC, which might contribute to the preferential settlement of indigenous bacteria on the FAE; they also suggest that differentiation into secretory cells is inhibited in the epithelium of the follicular sides of FAIC, so that differentiation into M cells might be admitted in the FAE of rat Peyer's patches. Furthermore, intermediate cells possessing characteristics of both Paneth cells and goblet cells were rarely found in the FAIC, but not in the IC. This finding suggests that the manner of differentiation into Paneth cells in the FAIC differs from that in the IC.
The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. Cecilie T Freddie, Søren S Larsen, Monica Bartholomaeussen, Anne E Lykkesfeldt Molecular and cellular endocrinology
219
27-36
2004
The benzothiophene arzoxifene is a new 3rd generation selective estrogen receptor (ER) modulator (SERM). We have investigated the effect of arzoxifene on growth and gene expression in the estrogen receptor alpha (ERalpha) positive human breast cancer cell line MCF-7. Arzoxifene inhibits cell growth as effectively as the antiestrogen tamoxifen. Northern analysis revealed that arzoxifene exerts a statistically significant inhibition of pS2 and progesterone receptor B mRNA expression. Significant agonistic effect was observed on the antitrypsin mRNA expression. In contrast to estradiol and tamoxifen, arzoxifene does not upregulate cathepsin D mRNA and protein expression. The metabolite of arzoxifene (ARZm) is a more potent growth inhibitor of MCF-7 cells than arzoxifene. A tamoxifen resistant MCF-7 subline displayed a significant dose-dependent growth inhibition to ARZm, whereas an ICI 182,780 resistant cell line only responded to high concentration. Our results indicate that arzoxifene and especially ARZm are efficient growth inhibitors of ER positive human breast cancer cells, including tamoxifen resistant cells. Moreover, arzoxifene displays less estrogen agonistic effects in MCF-7 cells than tamoxifen.
A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene. Cecilie T Freddie, Gitte L Christensen, Anne E Lykkesfeldt Molecular and cellular endocrinology
220
97-107
2004
The development of resistance in tamoxifen-treated breast cancer patients and the estrogenic side effects of tamoxifen have lead to the design of many new drugs. The new SERM arzoxifene and its active metabolite desmethylarzoxifene (ARZm) inhibits growth of breast cancer cells and has less estrogenic effects than tamoxifen on gene expression. A cell line with acquired resistance to ARZm (MCF-7/ARZm(R)-1) was established from MCF-7 cells. MCF-7/ARZm(R)-1 cells responded to treatment with tamoxifen and the pure antiestrogen ICI 182,7870. The estrogen receptor alpha (ERalpha) level in MCF-7/ARZm(R)-1 cells was lower than in MCF-7 cells due to a destabilization of the receptor by ARZm. A significant reduction in the mRNA and protein level of some estrogen-regulated genes was observed in MCF-7/ARZm(R)-1 compared to MCF-7. However, both the level of the ERalpha and several ER-regulated gene products increased towards parental MCF-7 level upon withdrawal from ARZm, concomitant with an increase in the sensitivity of MCF-7/ARZm(R)-1 cells to ARZm treatment. These data show that ARZm resistant cells remain sensitive to treatment with both tamoxifen and to ICI 182,780. Furthermore, the partial reversion to ARZm sensitivity upon withdrawal of the SERM suggests that patients may benefit from a rechallenge with ARZm.